Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04104412 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Safety/Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-LDP) for Lumbar Discogenic Pain

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 31, 2025 to Dec 31, 2026
    • Study completion date: Jun 30, 2026 to Jun 30, 2027
    v8
  2. Re-verified, no change to tracked fieldsv7
  3. Primary completion date: Dec 31, 2024 to Dec 31, 2025
    • Study completion date: Jun 30, 2025 to Jun 30, 2026
    v6
  4. Primary completion date: Dec 31, 2023 to Dec 31, 2024
    • Study completion date: Dec 31, 2024 to Jun 30, 2025
    v5
  5. Primary completion date: Dec 31, 2022 to Dec 31, 2023v4
Show 2 earlier versionsHide 2 earlier versions
  1. Primary completion date: Nov 1, 2021 to Dec 31, 2022
    • Study completion date: Jul 31, 2024 to Dec 31, 2024
    • Study title expanded, about 1 word
    v3
  2. Primary completion date: Feb 1, 2020 to Nov 1, 2021
    • Site contact updated
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This experimental use umbilical cord mesenchymal stem cells in treatment of the early stage of lumbar discogenic pain (endogenous pain of the disc) to evaluate its safety and efficacy. This experimental is mainly aimed at over 18years old people, regardless of gender, with refractory and persistent back pain for more than 6 months. The efficacy and safety of mesenchymal stem cells (MSCS) were evaluated by low-temperature plasma ablation and intravertebral disc injection, which were divided into treatment group and control group.
Trial Details
NCT Number NCT04104412
Lead Sponsor Sclnow Biotechnology Co., Ltd.
Conditions
(from sponsor)		 Lumbar Discogenic Pain
Enrollment 242 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov